Gene Synthesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Gene Synthesis Market is projected to expand from USD 2.11 Billion in 2025 to USD 3.73 Billion by 2031, registering a compound annual growth rate of 9.96%. Gene synthesis entails the de novo chemical engineering of double-stranded DNA sequences independent of natural templates, facilitating the precise creation of complex genes and genomes for biological investigation. This growth is largely fueled by the rising demand for personalized therapeutic strategies, the urgent requirement for rapid vaccine formulation, and substantial capital injections into the life sciences domain that support research and development activities. Highlighting this financial resurgence, SynBioBeta reported that venture investment in the synthetic biology sector hit $12.2 billion in 2024, indicating robust funding levels essential for sustaining industrial expansion and fostering technological breakthroughs.

Despite this favorable outlook, the market encounters substantial hurdles related to biosecurity risks linked to the potential exploitation of synthetic DNA. Anxieties regarding the accidental or malicious generation of dangerous pathogens have compelled governments and international organizations to enforce strict regulatory frameworks and screening procedures. These mandatory compliance measures impose higher operational expenses and significant administrative loads on manufacturers, leading to potential production delays and hindering the broader proliferation of the global gene synthesis market.

Market Drivers

Improvements in high-throughput DNA synthesis technologies are markedly speeding up the integration of synthetic biology into both industrial and research environments. Advances in silicon-based and enzymatic synthesis enable the large-scale production of complex, high-fidelity gene sequences with faster turnaround times, effectively eliminating past constraints in the design-build-test-learn cycle. This operational scalability permits commercial suppliers to satisfy the growing volume demands of researchers who are increasingly outsourcing the creation of variant libraries and metabolic pathways. For instance, Twist Bioscience revealed in its "Twist Bioscience Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results" from November 2024 that it shipped roughly 772,000 genes over the fiscal year, signaling a significant rise in the adoption of scalable synthesis technologies compared to previous periods.

The market is further bolstered by the broadening clinical development pipelines for gene and cell therapies, which generate a continuous demand for GMP-grade synthetic DNA essential for viral vector production and mRNA therapeutic templates. As pharmaceutical entities progress candidates from discovery stages to regulated clinical trials, the need for exact genetic materials to guarantee therapeutic safety and efficacy grows steadily. According to the "Gene, Cell, & RNA Therapy Landscape: Q1 2024 Quarterly Report" by the American Society of Gene + Cell Therapy in April 2024, the global pipeline has swelled to encompass 4,016 gene, cell, and RNA therapies, highlighting the immense raw material requirements. To support this growth, new market players are leveraging investor interest to expand manufacturing capabilities; for example, Elegen raised $35 million in Series B financing in 2024 to commercialize its proprietary cell-free DNA manufacturing infrastructure.

Market Challenges

The global gene synthesis market faces considerable obstacles arising from biosecurity threats linked to the possible misuse of synthetic DNA. Worries over the engineering of hazardous pathogens have mandated the implementation of rigorous regulatory structures and screening protocols. These compliance requirements compel manufacturers to incorporate expensive and time-intensive verification systems into their workflows, which directly elevates operational overhead and prolongs product delivery schedules.

The weight of these security precautions disproportionately impacts market flexibility and scalability. Firms are required to dedicate significant resources to administrative vetting procedures and "Know Your Customer" verifications instead of focusing solely on production velocity or technological innovation. As noted by the International Gene Synthesis Consortium in 2024, over 40 leading gene synthesis providers have pledged adherence to the Harmonized Screening Protocol to comply with these stringent biosecurity norms. While such widespread compliance is essential for ensuring public safety, the consequent rise in procedural intricacy serves as a hindrance to manufacturing efficiency, thereby curbing the overall growth potential of the gene synthesis industry.

Market Trends

The rise of DNA data storage as a new application vertical is transforming the market by tackling the severe constraints of conventional digital archiving. With global data generation exceeding the capabilities of magnetic and silicon-based storage media, synthetic DNA presents an alternative boasting superior volumetric density and durability, capable of preserving information for thousands of years. This application necessitates the synthesis of immense volumes of coding oligonucleotides, generating a fresh high-volume revenue source for gene synthesis providers separate from biological research requirements. For example, Twist Bioscience announced in a May 2025 press release titled "Twist Bioscience Spins Out DNA Data Storage as Independent Company" that it had obtained $155 million in seed funding for its new subsidiary, Atlas Data Storage, to bring this archival technology to market and address the rising demand for long-term data preservation.

A fundamental shift from centralized service models to on-site manufacturing is being driven by the adoption of decentralized benchtop DNA printing platforms. Laboratories are increasingly incorporating automated synthesizers to manufacture genetic material within their own facilities, thereby removing shipping delays and reducing intellectual property risks linked to outsourcing. This change enables researchers to iterate designs swiftly, shortening development timelines for vaccines and metabolic engineering initiatives without dependence on external suppliers. According to a March 2025 announcement titled "Telesis Bio Raises $21 Million from Novalis LifeSciences and Northpond Ventures," Telesis Bio secured this funding specifically to hasten the commercial rollout of its automated benchtop synthesis systems, emphasizing the industry's strategic move toward distributed manufacturing capabilities.

Key Players Profiled in the Gene Synthesis Market

• OriGene Technologies, Inc.
• Integrated DNA Technologies, Inc.
• ProMab Biotechnologies, Inc.
• Thermo Fisher Scientific, Inc.
• ProteoGenix, Inc.
• Biomatik USA LLC
• Twist Bioscience Corp.
• Boster Biological Technology Inc.
• Brooks Automation, Inc.
• Genscript Corporation

Report Scope

In this report, the Global Gene Synthesis Market has been segmented into the following categories:

Gene Synthesis Market, by Method:

• Solid-phase Synthesis
• Chip-based Synthesis
• PCR-based Enzyme Synthesis

Gene Synthesis Market, by Service:

• Antibody DNA Synthesis
• Viral DNA Synthesis
• Others

Gene Synthesis Market, by Application:

• Gene & Cell Therapy Development
• Vaccine Development
• Disease Diagnosis
• Others

Gene Synthesis Market, by End Use:

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations

Gene Synthesis Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Synthesis Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.